Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.

The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Inclusion Criteria:

• Aged ≥ 18 years old
• Diagnosis of stage IV melanoma
• Able to comprehend the investigational nature of the protocol and provide informed consent

Exclusion Criteria:

• Female patients who are currently pregnant or nursing
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Inability to perform regular electronic reporting

Patients with stage IV melanoma who are actively considering enrolling in a clinical study for said condition, but have not yet completed enrollment and randomization.